Sildenafil Drug Interactions: What Can Change Safety or Exposure

What Are Sildenafil Drug Interactions?

A sildenafil drug interaction occurs when another medicine or substance changes sildenafil pharmacological effects, safety or systemic exposure. The interaction can be pharmacodynamic, meaning two agents influence the same physiological pathway, or pharmacokinetic, meaning one agent changes sildenafil concentrations.

The interaction category matters because not all findings have the same regulatory consequence. Nitrates and guanylate cyclase stimulators are contraindicated, alpha-blockers require caution because of additive hypotension, and CYP3A4 inhibitors can require product-specific dosage modification because exposure rises.

A useful interaction review therefore asks three separate questions: what mechanism is involved, how large the demonstrated effect is, and how the applicable product label classifies the combination.

Drug Interactions vs Contraindications

A drug interaction is a broad category, whereas a contraindication is a stronger label-defined restriction. An interaction can exist without making concomitant use formally contraindicated.

Current sildenafil labeling places organic nitrates or nitrites and guanylate cyclase stimulators such as riociguat in the contraindication category because sildenafil can potentiate their hypotensive effects.

Alpha-blockers, antihypertensives and CYP3A4 inhibitors illustrate different categories: they can produce clinically important interactions, but their management is described through warnings, precautions or dosage provisions rather than by automatically classifying every combination as contraindicated.

Sildenafil and Nitrate Interactions

Organic nitrates and nitrites are among the most important sildenafil interactions because the combination is formally contraindicated in current U.S. labeling. This applies to nitric oxide donors in any form and includes regular as well as intermittent nitrate use.

The mechanism is pharmacodynamic. Nitrates increase nitric oxide–cGMP signaling, while sildenafil inhibits PDE5-mediated cGMP breakdown. Combining the two can amplify vasodilation and produce excessive blood-pressure lowering.

The label also states that after sildenafil has been taken, the time at which nitrates could subsequently be administered safely is unknown, including at 24 hours. Because this interaction has its own high-priority safety context, detailed coverage remains on the dedicated resource.

Sildenafil and Riociguat Interaction

Riociguat is a guanylate cyclase stimulator and its concomitant use with sildenafil is contraindicated in current U.S. labeling. This is a pharmacodynamic interaction rather than an enzyme-mediated exposure interaction.

Riociguat stimulates soluble guanylate cyclase and increases cGMP signaling, while sildenafil slows cGMP degradation through PDE5 inhibition. Combining these mechanisms can potentiate hypotensive effects.

The important distinction for an interaction hub is regulatory classification: riociguat belongs with the formal contraindications rather than with combinations that merely require routine caution. Detailed pharmacological discussion remains on the dedicated page.

CYP3A4-Mediated Sildenafil Interactions

Sildenafil is metabolized principally through CYP3A4, with CYP2C9 providing a smaller contribution. Medicines that inhibit CYP3A4 can reduce sildenafil metabolic clearance and increase circulating exposure, while CYP3A induction can reduce exposure.

The magnitude can be large. Current ED-oriented labeling reports an approximately 11-fold increase in sildenafil AUC with ritonavir. Erythromycin increased Cmax by approximately 160% and AUC by 182%, while saquinavir increased Cmax by approximately 140% and AUC by 210%.

Those results demonstrate why the interaction category cannot be reduced to a generic statement that levels 'may rise.' The enzyme mechanism itself is examined on the sildenafil CYP3A4 page, while this hub focuses on how that mechanism fits among other interaction classes.

Enzyme Inhibitors and Sildenafil Exposure

CYP3A4 inhibitors reduce metabolic capacity available for sildenafil clearance. The result can be higher parent-drug concentrations, greater AUC and persistence of higher concentrations later in the concentration-time profile.

Different inhibitors produce different magnitudes of interaction. Ritonavir is an especially strong example because it inhibits multiple P450 pathways and produced an approximately 11-fold increase in sildenafil AUC in the labeled interaction study. Erythromycin and saquinavir produced smaller but still substantial increases.

The clinical consequence is therefore substance-specific rather than determined solely by the word inhibitor. Current ED labeling contains explicit dosage provisions for ritonavir and recommends consideration of a lower starting dose with erythromycin or strong CYP3A4 inhibitors.

Enzyme Inducers and Sildenafil Exposure

Enzyme induction acts in the opposite pharmacokinetic direction from inhibition. Increased CYP-mediated metabolic capacity can accelerate removal of parent sildenafil and decrease systemic exposure.

Bosentan provides a quantitative example from sildenafil clinical pharmacology. In a healthy-volunteer interaction study, bosentan, an inducer of CYP3A4, CYP2C9 and possibly CYP2C19, reduced sildenafil AUC by approximately 63% and Cmax by approximately 55%.

Because bosentan affects multiple CYP pathways, those percentages should not be attributed to CYP3A4 alone. Current PAH labeling also states that strong CYP3A inducers are expected to cause substantial reductions in sildenafil plasma levels, demonstrating why interaction interpretation can differ by product and indication.

Blood Pressure-Related Interactions

Sildenafil has systemic vasodilatory effects, so medicines that also lower blood pressure can produce additive effects even when the combination is not formally contraindicated. The regulatory significance depends on the drug class and the evidence for the specific combination.

Amlodipine provides a measured example. When sildenafil 100 mg was coadministered with amlodipine 5 mg or 10 mg in hypertensive patients, the mean additional reduction in supine blood pressure was approximately 8 mmHg systolic and 7 mmHg diastolic.

This interaction differs fundamentally from nitrates. Antihypertensive therapy can require caution and assessment, whereas nitrates and riociguat are formal contraindications. Other PDE5 inhibitors or other ED therapies are also not recommended in current ED labeling because combined use has not been adequately studied and may further lower blood pressure.

Sildenafil and Alpha-Blocker Interaction Context

Alpha-blockers and sildenafil can both lower vascular resistance, creating the potential for additive blood-pressure reduction and symptomatic hypotension in susceptible patients.

Current ED sildenafil labeling therefore advises caution with coadministration. It states that patients should be stable on alpha-blocker therapy before sildenafil is initiated and uses a lower sildenafil starting-dose framework in that interaction context.

Alpha-blocker use is not classified in the same way as nitrate use. The relevant distinction is caution and blood-pressure management rather than a universal contraindication.

Food, Alcohol and Sildenafil Interaction Context

Food and alcohol are usually discussed separately from conventional medication interactions because their mechanisms and evidence differ. A high-fat meal primarily changes sildenafil absorption, while alcohol raises a separate pharmacodynamic safety question.

Current labeling reports that a high-fat meal delays mean sildenafil Tmax by approximately 60 minutes and lowers mean Cmax by approximately 29%. This is a food-effect pharmacokinetic finding rather than a contraindicated interaction.

In a controlled interaction study, sildenafil 50 mg given with alcohol 0.5 g/kg, producing a mean maximum blood alcohol level of about 0.08%, did not potentiate alcohol's hypotensive effect in healthy volunteers. That limited study does not establish the effect of every alcohol exposure or sildenafil regimen. Detailed interpretation remains on the sildenafil food-effects page and sildenafil alcohol page.

Drug Interactions and Sildenafil Exposure

Pharmacokinetic interactions can change several features of the sildenafil concentration-time profile at once. Cmax describes peak concentration, AUC describes integrated exposure and late plasma concentrations show how long elevated systemic levels can persist.

Ritonavir demonstrates why multiple PK metrics matter. In the labeled interaction study, sildenafil Cmax increased approximately fourfold and AUC approximately elevenfold; at 24 hours, sildenafil concentrations remained around 200 ng/mL compared with approximately 5 ng/mL when sildenafil was given alone.

Bosentan demonstrates the opposite direction, reducing sildenafil AUC and Cmax. These examples show that a drug interaction can reshape the entire concentration-time profile rather than simply producing a generic increase or decrease in one laboratory number.

Why Sildenafil Interaction Risk Depends on Context

Interaction significance depends on more than the name of the interacting drug. The same mechanistic category can produce very different quantitative effects, and the relevant regulatory recommendation can differ according to sildenafil indication and product labeling.

ED-oriented sildenafil labeling, for example, provides specific provisions for alpha-blockers, ritonavir and other CYP3A4 inhibitors. Current PAH-oriented REVATIO labeling has its own interaction framework, including a recommendation against strong CYP3A inhibitor coadministration and separate guidance for moderate-to-strong CYP3A inducers such as bosentan.

Medication lists also require attention to therapeutic duplication. Sildenafil is marketed in different products and indications, and current labeling advises against combining sildenafil-containing PAH treatment with VIAGRA or other PDE5 inhibitors. A general interaction hub can identify these categories, but the specific product label and clinical context determine the applicable action.

Related Sildenafil Interaction Resources

The interaction framework can be divided into three major mechanisms: excessive cGMP-mediated vasodilation, additive blood-pressure lowering and changes in CYP-mediated sildenafil exposure.

Nitrates and riociguat require dedicated treatment because they are formal contraindications. CYP3A4 interactions require separate pharmacokinetic analysis because their magnitude can range from moderate exposure shifts to the approximately elevenfold AUC increase observed with ritonavir. Food and alcohol remain adjacent but distinct interaction topics.